Online inquiry

IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ3640MR)

This product GTTS-WQ3640MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets FGFR2 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000141.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2263
UniProt ID P21802
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ3640MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ3632MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1179470(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BAY 1179470
GTTS-WQ7341MR IVTScrip™ mRNA-Anti-VTCN1, FPA-150(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA FPA-150
GTTS-WQ6093MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ7078MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ15814MR IVTScrip™ mRNA-Anti-CD3E&IL3RA, XmAb14045(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA XmAb14045
GTTS-WQ14149MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA aIL6R88
GTTS-WQ14263MR IVTScrip™ mRNA-Anti-ERBB3, RG-7116(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA RG-7116
GTTS-WQ668MR IVTScrip™ mRNA-Anti-CD276, 8H9(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA 8H9
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW